# Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis

> **NCT02821689** · PHASE4 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 57 (estimated)

## Conditions studied

- Dermatopolymyositis
- Interstitial Lung Disease

## Interventions

- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT02821689
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2017-06
- **Final completion:** 2018-06
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2016-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821689, "Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02821689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*